Analysis of Immunological Response and QOL with adoptive transfer of T cells in cancer patients

由于2型细胞因子的影响或淋巴细胞的减少，癌症患者的生活质量（QOL）往往较低。为了评估接受活化T细胞转移的癌症患者的QOL，通过在FACIT翻译项目程序和指南中使用的迭代前向-后向翻译序列开发了癌症治疗功能评估-生物反应修饰剂（FACT-BRM）的日语版本。完成了FACT-BRM日文版的初步测试，发现问卷项目易于理解，没有不相关或冒犯性的。在对试点研究的结果进行分析后，FACT-BRM的日文版定稿。采用FACT-BRM-TOI（试验结果指数）评估62例接受活化T细胞移植的癌症患者的生活质量。62例患者中有25例（40%）在活化T细胞转移后QOL评分增加。在患者中，CD 8 P + CD 28 + T细胞和CD 3 + CXCR 3 + T细胞在T细胞转移后数量增加。因此，活化的T细胞转移可以由于增加体内1型T细胞的数量而改善癌症患者的生活质量。需要进一步的实验来验证活化T细胞转移对改善癌症患者的生活质量的有效性，以与在相同背景下未接受活化T细胞转移的患者进行比较。

Quality of life (QOL) in cancer patients is often lower because of the influence of Type 2 cytokine or decrease of the lymphocyte. To assess QOL in cancer patients who received the activated T cell transfer, the Japanese version of the Functional Assessment of Cancer Therapy-Biological Response Modifier (FACT-BRM) was developed through an iterative forward-backward translation sequence used throughout the FACIT Translation Project Procedures and Guidelines. The Pilot testing of the Japanese version of FACT-BRM was done and questionnaire items were found easy to understand, and none were irrelevant or offensive. After the analysis of the results of the pilot study, the Japanese version of the FACT-BRM was finalized. The FACT-BRM-TOI (trial outcome index) was used to assess QOL in 62 cancer patients who received the activated T cell transfer. In 25 of 62 (40%) patients, QOL scores increased after the activated T cell transfer. In the patients, CD8P+CD28+ T cells and CD3+CXCR3+ T cells increased in their numbers after the T cell transfer. Therefore, the activated T cell transfer could improve QOL in cancer patients due to increase the number of Type 1 T cells in vivo. Further experiments are needed to verify the effectiveness of the activated T cell transfer to improve QOL in cancer patients to compare with that of the patients who do not receive the activated T cell transfer in the same background.